Published in J Pharmacol Exp Ther on October 14, 2008
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6.55
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study. Neurology (2010) 1.78
Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.38
Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neurochem (2014) 1.37
Developing β-secretase inhibitors for treatment of Alzheimer's disease. J Neurochem (2011) 1.37
Animal models of Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.18
BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease. Chem Soc Rev (2014) 1.14
Phospho-eIF2α level is important for determining abilities of BACE1 reduction to rescue cholinergic neurodegeneration and memory defects in 5XFAD mice. PLoS One (2010) 1.11
Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J Neurosci (2010) 1.09
The Membrane-Bound Aspartyl Protease BACE1: Molecular and Functional Properties in Alzheimer's Disease and Beyond. Front Physiol (2012) 1.09
Nonhuman primate models of Alzheimer-like cerebral proteopathy. Curr Pharm Des (2012) 1.06
beta-Secretase inhibitor potency is decreased by aberrant beta-cleavage location of the "Swedish mutant" amyloid precursor protein. J Biol Chem (2009) 0.96
Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem (2012) 0.96
BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system. PLoS One (2012) 0.89
CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition. J Neurosci (2014) 0.84
Mechanisms that lessen benefits of β-secretase reduction in a mouse model of Alzheimer's disease. Transl Psychiatry (2013) 0.84
Label-free Quantitative Proteomics of Mouse Cerebrospinal Fluid Detects β-Site APP Cleaving Enzyme (BACE1) Protease Substrates In Vivo. Mol Cell Proteomics (2015) 0.81
BACE-1 inhibition prevents the γ-secretase inhibitor evoked Aβ rise in human neuroblastoma SH-SY5Y cells. J Biomed Sci (2011) 0.81
Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. Alzheimers Res Ther (2010) 0.77
AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics. J Alzheimers Dis (2016) 0.76
Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model. PLoS One (2015) 0.75
Pharmacological applications of a novel neoepitope antibody to a modified amyloid precursor protein-derived beta-secretase product. Protein Cell (2011) 0.75
Alzheimer's disease biomarkers in animal models: closing the translational gap. Am J Neurodegener Dis (2013) 0.75
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature (2002) 12.49
Prevalence and control of diabetes in Chinese adults. JAMA (2013) 11.73
The challenge of finding a cure for HIV infection. Science (2009) 8.41
APP processing and synaptic function. Neuron (2003) 8.37
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe (2008) 6.24
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses (2009) 4.32
Trends in prevalence of HIV, syphilis, hepatitis C, hepatitis B, and sexual risk behavior among men who have sex with men. Results of 3 consecutive respondent-driven sampling surveys in Beijing, 2004 through 2006. J Acquir Immune Defic Syndr (2007) 3.83
Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods (2004) 3.53
Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res (2006) 2.96
Complete genome sequence of Yersinia pestis strain 91001, an isolate avirulent to humans. DNA Res (2004) 2.95
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther (2007) 2.91
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis (2011) 2.66
1-(2-Chloro-phen-yl)-2-(isopropyl-amino)ethanol. Acta Crystallogr Sect E Struct Rep Online (2009) 2.65
A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A (2004) 2.55
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol (2011) 2.41
A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol (2009) 2.30
Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc Natl Acad Sci U S A (2004) 2.30
Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS (2009) 2.28
Transforming the untransformable: application of direct transformation to manipulate genetically Staphylococcus aureus and Staphylococcus epidermidis. MBio (2012) 2.26
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res (2007) 2.25
c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol (2007) 2.24
Consumption of whole grains and cereal fiber and total and cause-specific mortality: prospective analysis of 367,442 individuals. BMC Med (2015) 2.22
Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol (2009) 2.19
Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science (2004) 2.12
Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal (2008) 2.05
Genetics of metabolic variations between Yersinia pestis biovars and the proposal of a new biovar, microtus. J Bacteriol (2004) 2.04
Structure-based design of novel inhibitors of the MDM2-p53 interaction. J Med Chem (2012) 2.01
Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol (2010) 2.01
IgE⁺ memory B cells and plasma cells generated through a germinal-center pathway. Nat Immunol (2012) 2.00
Impact of the Serum Uric Acid Level on Subclinical Atherosclerosis in Middle-aged and Elderly Chinese. J Atheroscler Thromb (2015) 2.00
IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol (2011) 1.95
A presenilin dimer at the core of the gamma-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolysis. Proc Natl Acad Sci U S A (2003) 1.92
Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem (2002) 1.89
Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). J Med Chem (2004) 1.87
Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with Burkitt lymphoma/leukemia. Pediatr Blood Cancer (2008) 1.85
Use of erythrocyte sedimentation rate and C-reactive protein level to diagnose infection before revision total knee arthroplasty. A prospective evaluation. J Bone Joint Surg Am (2007) 1.84
HIF-1α and HIF-2α correlate with migration and invasion in gastric cancer. Cancer Biol Ther (2010) 1.83
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother (2009) 1.80
Relationship of urinary bisphenol A concentration to risk for prevalent type 2 diabetes in Chinese adults: a cross-sectional analysis. Ann Intern Med (2011) 1.74
Notch-induced E2A ubiquitination and degradation are controlled by MAP kinase activities. EMBO J (2003) 1.73
Cross-sectional and longitudinal association of serum alanine aminotransaminase and γ-glutamyltransferase with metabolic syndrome in middle-aged and elderly Chinese people. J Diabetes (2011) 1.71
Further understanding human disease genes by comparing with housekeeping genes and other genes. BMC Genomics (2006) 1.68
Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol (2012) 1.66
Physical properties of alginate hydrogels and their effects on in vitro follicle development. Biomaterials (2007) 1.66
Apoptosis and mitochondrial dysfunction in human chondrocytes following exposure to lidocaine, bupivacaine, and ropivacaine. J Bone Joint Surg Am (2010) 1.63
Urinary bisphenol A (BPA) concentration associates with obesity and insulin resistance. J Clin Endocrinol Metab (2011) 1.63
N-[2-(2-Chloro-phen-yl)-2-hydroxy-ethyl]propan-2-aminium hemioxalate. Acta Crystallogr Sect E Struct Rep Online (2009) 1.62
Confirmatory reanalysis of incurred bioanalytical samples. AAPS J (2007) 1.62
Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg Med Chem Lett (2008) 1.62
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods (2008) 1.60
Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J Med Chem (2003) 1.55
Presenilin-1 and presenilin-2 exhibit distinct yet overlapping gamma-secretase activities. J Biol Chem (2003) 1.54
Xanthomonas campestris cell-cell communication involves a putative nucleotide receptor protein Clp and a hierarchical signalling network. Mol Microbiol (2007) 1.53
DNA microarray analysis of genome dynamics in Yersinia pestis: insights into bacterial genome microevolution and niche adaptation. J Bacteriol (2004) 1.52
A novel pathway for amyloid precursor protein processing. Neurobiol Aging (2009) 1.52
LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.50
MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother (2012) 1.48
Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol (2008) 1.48
15000 unique zebrafish EST clusters and their future use in microarray for profiling gene expression patterns during embryogenesis. Genome Res (2003) 1.46
Interpenetrating fibrin-alginate matrices for in vitro ovarian follicle development. Biomaterials (2009) 1.46
An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe (2013) 1.46
Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum. J Pharm Biomed Anal (2005) 1.45
Replication studies using genotype 1a subgenomic hepatitis C virus replicons. J Virol (2003) 1.42
Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. Mol Cancer Ther (2010) 1.41
Genome scale analysis of diffusible signal factor regulon in Xanthomonas campestris pv. campestris: identification of novel cell-cell communication-dependent genes and functions. Mol Microbiol (2006) 1.41
Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor. Antimicrob Agents Chemother (2003) 1.40
Variants in glucose- and circadian rhythm-related genes affect the response of energy expenditure to weight-loss diets: the POUNDS LOST Trial. Am J Clin Nutr (2013) 1.40
Reduction of intracellular pH inhibits the expression of VEGF in K562 cells after targeted inhibition of the Na+/H+ exchanger. Leuk Res (2006) 1.39
A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum (2009) 1.38
Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice. J Clin Invest (2010) 1.36
Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol (2010) 1.34
Persistent replication of hepatitis C virus replicons expressing the beta-lactamase reporter in subpopulations of highly permissive Huh7 cells. J Virol (2003) 1.33
Plasmodesmata during development: re-examination of the importance of primary, secondary, and branched plasmodesmata structure versus function. Protoplasma (2010) 1.31
Inhibition of human immunodeficiency virus type 1 concerted integration by strand transfer inhibitors which recognize a transient structural intermediate. J Virol (2007) 1.30
Altering expression levels of human immunodeficiency virus type 1 gp120-gp41 affects efficiency but not kinetics of cell-cell fusion. J Virol (2002) 1.29
A spermatogenesis-related gene expression profile in human spermatozoa and its potential clinical applications. J Mol Med (Berl) (2004) 1.28
Application of the Toyota Production System improves core laboratory operations. Am J Clin Pathol (2010) 1.28